A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma.

Trial Profile

A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination With Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients With Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent Non-Hodgkin's Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Ibrutinib (Primary) ; Bendamustine; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Apr 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 31 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Mar 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top